Abstract:Background: Evaluating outcome reliability is critical in real-world evidence studies. Overall survival is a common outcome in these studies; however, its capture in real-world data (RWD) sources is often incomplete and supplemented with linked mortality information from external sources. Conflicting recommendations exist for censoring overall survival in real-world evidence studies. This simulation study aimed to understand the impact of different censoring methods on estimating median survival and log hazard ratios when external mortality information is partially captured. Methods: We used Monte Carlo simulation to emulate a non-randomized comparative effectiveness study of two treatments with RWD from electronic health records and linked external mortality data. We simulated the time to death, the time to last database activity, and the time to data cutoff. Death events after the last database activity were attributed to linked external mortality data and randomly set to missing to reflect the sensitivity of contemporary real-world data sources. Two censoring schemes were evaluated: (1) censoring at the last activity date and (2) censoring at the end of data availability (data cutoff) without an observed death. We assessed the performance of each method in estimating median survival and log hazard ratios using bias, coverage, variance, and rejection rate under varying amounts of incomplete mortality information and varying treatment effects, length of follow-up, and sample size. Results: When mortality information was fully captured, median survival estimates were unbiased when censoring at data cutoff and underestimated when censoring at the last activity. When linked mortality information was missing, censoring at the last activity date underestimated the median survival, while censoring at the data cutoff overestimated it. As missing linked mortality information increased, bias decreased when censoring at the last activity date and increased when censoring at data cutoff. Conclusions: Researchers should consider the completeness of linked external mortality information when choosing how to censor the analysis of overall survival using RWD. Substantial bias in median survival estimates can occur if an inappropriate censoring scheme is selected. We advocate for RWD providers to perform validation studies of their mortality data and publish their findings to inform methodological decisions better.

Effect of difference censored rates between groups in clinical trails

Comparison of baseline covariate adjustment methods for restricted mean survival time

Exploring Statistical Methods in Clinical Trials When Some of the Patients are Treated against the Randomization

The Effect of Sample Size and Censoring Proportion on the Power and Bias of Survival Analysis Models

Estimate Risk Difference and Number Needed to Treat in Survival Analysis.

Covariate-adjusted Group Sequential Comparisons of Survival Probabilities

Is inverse probability of censoring weighting a safer choice than per-protocol analysis in clinical trials?

Association of differential censoring with survival and suboptimal control arms among oncology clinical trials

ASSESSING THE HETEROGENEITY OF TREATMENT EFFECTS BY IDENTIFYING THE TREATMENT BENEFIT RATE AND TREATMENT HARM RATE

Scaling and interpreting treatment effects in clinical trials using restricted mean survival time

The impact of different censoring methods for analyzing survival using real-world data with linked mortality information: a simulation study

A nonparametric relative treatment effect for direct comparisons of censored paired survival outcomes

Multiple random change points in survival analysis with applications to clinical trials

A General Theory on Stochastic Curtailment for Censored Survival Data

Influence of Center Effects and Imbalanced Sample Sizes Between Centers on Therapeutic Evaluation in Clinical Trials

Sample size calculation based on the difference in restricted mean time lost for clinical trials with competing risks

Estimating the Causal Effects in Randomized Trials for Survival Data with A Cure Fraction and Non Compliance

A novel statistical method for comparing effectiveness of two treatments-simulated randomized controlled trials

Design and Analysis of Clinical Trials in the Presence of Delayed Treatment Effect

Which Test for Crossing Survival Curves? A User's Guideline.

Statistical performance comparison of different design methods of targeted clinical trials